iBody
Advancing health and quality of life with innovative monoclonal antibody tech from minimal blood samples to enhance treatment and diagnostics.
Advancing health and quality of life with innovative monoclonal antibody tech from minimal blood samples to enhance treatment and diagnostics.
iBody is a promising startup that emerged in 2018 with a mission to revolutionize the field of health and quality of life. Hailing from Nagoya University Graduate School of Life and Agriculture, this innovative venture is making strides in the Care Economy, Health Care, and Human Resources sectors. iBody's pioneering approach involves harnessing monoclonal antibody extraction technology from minimal blood samples, with the goal of enhancing treatment and diagnostic techniques, and advancing life sciences. This breakthrough has the potential to significantly improve human health and quality of life. Notably, iBody secured a remarkable ¥150.00M Venture Round investment on 31 July 2020, with support from esteemed investors such as Nissay Capital, Ogaki Kyoritsu Bank, and Juroku Lease. With such impressive advancements and strong investor backing, iBody is undoubtedly a startup to watch in the evolving landscape of health and life sciences.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | ¥150.00M | 3 |
|
31 Jul 2020 |
| Seed Round | ¥100.00M | 1 |
|
16 May 2018 |
No recent news or press coverage available for iBody.
We care about your data, and we'd love to use cookies make your experience better.
